Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal

Affiliations

¹ From the Department of Renal Medicine, Concord Repatriation General Hospital (AA), Concord Clinical School, Faculty of Medicine and Health, University of Sydney (AA), Drug Health Services and Clinical Pharmacology and Toxicology, Royal Prince Alfred Hospital (AA, NJ, DMR), New South Wales Poisons Information Centre, Sydney Children's Hospital Network (NJ, DMR), Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, New South Wales, Australia (DMR), Department of Renal Medicine and Transplantation, St Vincent's Hospital (DMR) and St Vincent's Clinical School, University of New South Wales, New South Wales, Australia (DMR).

Comment

Akshay Athavale et al. Eur J Anaesthesiol. 2021.

. 2021 Sep 1;38(9):1005-1006.

doi: 10.1097/EJA.0000000000001428.

¹ From the Department of Renal Medicine, Concord Repatriation General Hospital (AA), Concord Clinical School, Faculty of Medicine and Health, University of Sydney (AA), Drug Health Services and Clinical Pharmacology and Toxicology, Royal Prince Alfred Hospital (AA, NJ, DMR), New South Wales Poisons Information Centre, Sydney Children's Hospital Network (NJ, DMR), Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, New South Wales, Australia (DMR), Department of Renal Medicine and Transplantation, St Vincent's Hospital (DMR) and St Vincent's Clinical School, University of New South Wales, New South Wales, Australia (DMR).

No abstract available

Comment on

Idarucizumab for dabigatran reversal in daily clinical practice: A case series.
Vene N, Mavri A, Božič-Mijovski M, Gregorič M, Uštar KK, Žerjav U, Gradišek P, Stecher A, Frol S, Nedog V, Detkova N, Kosi IE. Vene N, et al. Eur J Anaesthesiol. 2020 Oct;37(10):874-878. doi: 10.1097/EJA.0000000000001185. Eur J Anaesthesiol. 2020. PMID: 32175987

1. Vene N, Mavri A, Božič-Mijovski M, et al. Idarucizumab for dabigatran reversal in daily clinical practice: a case series. Eur J Anaesthesiol 2020; 37:874–878.
1. Athavale A, Jamshidi N, Roberts DM. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clin Toxicol (Phila) 2020; 58:789–800.
1. Yasaka M, Ikushima I, Harada A, et al. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Res Pract Thromb Haemost 2017; 1:202–215.